Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives $24.00 Average PT from Brokerages

Posted by Brenda Bartman on Jun 29th, 2026

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Get Free Report) has been assigned an average rating of “Reduce” from the eight brokerages that are presently covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation and six have given a hold recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $24.00.

Several brokerages recently issued reports on AMPH. Barclays dropped their target price on shares of Amphastar Pharmaceuticals from $23.00 to $20.00 and set an “equal weight” rating on the stock in a report on Wednesday, June 3rd. Jefferies Financial Group restated a “hold” rating and issued a $22.00 target price (down from $30.00) on shares of Amphastar Pharmaceuticals in a report on Tuesday, April 21st. Zacks Research cut shares of Amphastar Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Monday, June 22nd. Needham & Company LLC restated a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Friday, May 8th. Finally, Piper Sandler restated a “neutral” rating and issued a $21.00 target price (down from $25.00) on shares of Amphastar Pharmaceuticals in a report on Monday, May 11th.

Get Our Latest Stock Report on Amphastar Pharmaceuticals

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP raised its position in Amphastar Pharmaceuticals by 12.7% in the first quarter. Dimensional Fund Advisors LP now owns 2,027,947 shares of the company’s stock worth $39,726,000 after acquiring an additional 228,262 shares during the period. TD Asset Management Inc raised its position in Amphastar Pharmaceuticals by 1.6% in the fourth quarter. TD Asset Management Inc now owns 1,963,052 shares of the company’s stock worth $52,571,000 after acquiring an additional 31,160 shares during the period. State Street Corp raised its position in Amphastar Pharmaceuticals by 2.1% in the fourth quarter. State Street Corp now owns 1,531,786 shares of the company’s stock worth $41,021,000 after acquiring an additional 31,044 shares during the period. Fuller & Thaler Asset Management Inc. raised its position in Amphastar Pharmaceuticals by 3.0% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 1,394,463 shares of the company’s stock worth $37,344,000 after acquiring an additional 40,536 shares during the period. Finally, Marshall Wace LLP raised its position in Amphastar Pharmaceuticals by 41.6% in the fourth quarter. Marshall Wace LLP now owns 1,237,284 shares of the company’s stock worth $33,134,000 after acquiring an additional 363,216 shares during the period. 65.09% of the stock is currently owned by institutional investors.

Amphastar Pharmaceuticals Stock Performance

Shares of AMPH stock opened at $21.78 on Monday. Amphastar Pharmaceuticals has a 12-month low of $16.65 and a 12-month high of $31.26. The company has a current ratio of 3.85, a quick ratio of 2.82 and a debt-to-equity ratio of 0.79. The firm’s 50 day moving average is $19.89 and its 200 day moving average is $22.85. The stock has a market capitalization of $960.28 million, a P/E ratio of 13.12, a P/E/G ratio of 4.28 and a beta of 0.91.

Amphastar Pharmaceuticals (NASDAQ:AMPH – Get Free Report) last issued its earnings results on Thursday, May 7th. The company reported $0.42 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.70 by ($0.28). Amphastar Pharmaceuticals had a return on equity of 15.12% and a net margin of 11.00%.The company had revenue of $171.17 million during the quarter, compared to analysts’ expectations of $173.46 million. Research analysts expect that Amphastar Pharmaceuticals will post 2.41 earnings per share for the current year.

Amphastar Pharmaceuticals Company Profile

(Get Free Report)

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.